New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was −187.2% in Q3 FY26, against a low of −1,032.3% in Q2 FY26.

ROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROIC0.0%0.0%−1032.3%−187.2%

Debt

Net debt is 7.35× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Debt / equity0.0×0.0×0.0×0.0×
Net debt / EBITDA5.7×5.0×5.1×7.3×
Dec '25 Mar '26 Jun '26 Sep '26
ROE
— — — (117.38%)
ROA
— — — (80.59%)
ROIC
0.00% 0.00% (1,032.33%) (187.24%)
Return on Tangible Assets
(61.07%) (83.95%) (52.72%) (64.37%)
Free Cash Flow per Share
(12.07) (13.32) (8.45) (2.46)
Free Cash Flow
(156.13) (193.60) (213.02) (226.76)
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026